- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04418401
Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients (CISLD-8)
A Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients With High Risks of Recurrence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Tingbo Liang, PhD
- Phone Number: +8613666676128
- Email: liangtingbo@zju.edu.cn
Study Contact Backup
- Name: Yiwen Chen, MD
- Phone Number: +8619941463683
- Email: yiwenchen0705@126.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- the First Affiliated Hospital, School of Medicine, Zhejiang University
-
Contact:
- Yiwen Chen, MD
- Phone Number: +8619941463683
- Email: yiwenchen0705@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1)Voluntary admission and signature of written informed consent;
2)18~75 years of age (including 75 years), male and female;
3)Hepatocellular carcinoma underwent radical resection 4~8 weeks before enrolled.
4)Pathologically diagnosed as hepatocellular carcinoma with any of the following conditions: a)Microvascular invasion (MVI); b)Satellite nodules were found in specimens; c)Multiple tumor nodules(>3 nodules); d)Portal vein tumor thrombosis (PVTT): The tumor thrombosis invades the left or right branches of portal vein, with or without hepatic vein invasion;
5)≥4 weeks after radical resection, the imaging examination confirmed no recurrence and metastasis.
6)Liver function Child-Pugh grade A (5~6);
7)Physical condition was scored 0~1 according to the ECOG criteria.
8)Expected lifetime >3 months;
9)HBV DNA<10^4 copy/ ml (2000 IU/ ml); if HBV DNA ≥10^4 copy/ ml, antiviral therapy should be given, until the HBV DNA drops below 10^4Copy/ml patient can be enrolled in the study. And during the study, antiviral drugs should be continued, and liver function and hepatitis B virus load should be monitored;
10)The results of the serum pregnancy test must be negative for women with fertility (i.e. non-menopausal or surgical sterilization) within 7 days prior to the study of drug administration;
11)The main organs function normally: Blood routine examination (no transfusion, no use of G-CSF within 14 days before screening): a)Hemoglobin ≥90 g/L; b)Absolute neutrophil count (ANC)≥1.5×10^9/L; c)Platelet count ≥75×10^9/L; Blood biochemical examination (albumin not used within 14 days before screening): d)Albumin ≥28 g/L; e)Total bilirubin ≤1.5× ULN; f)Aspartate aminotransferase (AST), alanine aminotransferase (ALT )≤3× ULN; g)Serum creatinine ≤1.5×ULN; Coagulation function: h)The international standardized ratio (INR) or prothrombin time (PT )≤1.5×ULN;. i)Activated partial thromboplastin time (APTT )≤1.5×ULN.
Exclusion Criteria:
- Histopathological diagnosis of hepatocellular carcinoma - intrahepatic cholangiocarcinoma (HCC-ICC) mixed type;
- Positive resection margin or tumor rupture;
- Operation of recurrent liver cancer;
- Other malignancies within 5 years unless the patient has received a possible cure and there is no evidence of the disease within 5 years, but this time requirement (i.e. within 5 years) is not applicable to patients with skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ or other carcinoma in situ who have successfully undergone excision;
- Previous or present congenital or acquired immunodeficiency disease;
- Active or previously documented autoimmune or inflammatory diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, pituitary inflammation, hyperthyroidism or hypothyroidism, asthma requiring treatment with bronchiectasis, etc.), asthma with vitiligo or which has been completely relieved in childhood without inclusion of any intervention in adults;
- History of severe mental illness;
Suffer from diseases (e.g. severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.) that affect the absorption, distribution, metabolism or clearance of the study drug;
Past or combined medication/treatment:
- Had major surgery (defined by the investigators) within 4 weeks before admission, or expected to require major surgery during study therapy;
- Previous transplantation of allogeneic stem cells or parenchymal organs;
- Preoperative treatment with sorafenib, valvatinib, regofenib or immunomodulator such as anti PD-1、 PD-L1、 anti CTLA-4;
- Patients who have received other systemic anti-tumor treatments before surgery, including traditional Chinese medicine with anti-tumor indications, have had less than 2 weeks or 5 half-time (whichever is longer) between the completion of the treatment and the use of the drugs before the study, or who have not recovered to ≤CTCAE 1 level of adverse events caused by preoperative treatment;
- Other adjuvant therapy (except antiviral therapy) was performed after operation.
- Systemic immunosuppressive drugs have been used within 2 weeks before admission or are expected to be required during the study period, except in the following cases: a)Intra-nasal, inhalation, topical or topical (e.g. intra-articular) corticosteroids; b)Prednisone ≤ 10 mg/day or other equivalent systemic corticosteroid; c)Prophylactic use of corticosteroids for hypersensitivity;
- Take drugs that may prolong QTc and/or induce advanced torsional ventricular tachycardia (Tdp) or affect drug metabolism;
- Patients with known or suspected history of allergies to Donafenib or similar drugs, hypersensitivity to chimeric or humanized antibodies or fusion proteins, or to excipients used to study drugs;
- The presence of uncontrollable hepatic encephalopathy, hepatorenal syndrome, ascites, pleural effusion or pericardial effusion;
- Active bleeding or abnormal coagulation function, bleeding tendency or undergoing thrombolytic, anticoagulant or antiplatelet therapy;
- There was a history of gastrointestinal bleeding or a definite tendency of gastrointestinal bleeding in the past 4 weeks (e.g. local active ulcer lesions, stool occult blood≥ ++ , e.g. continuous stool occult blood +, gastroscopy should be performed), or other conditions (e.g. severe gastric fundus/esophageal varices) that the researchers determined might cause gastrointestinal bleeding;
- Gastrointestinal perforation, abdominal fistula or abdominal abscess occurred within 6 months.
- Thrombosis or thromboembolic events, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc., occurred within 6 months.
- With significant clinical significance, including but not limited to previous 6 months of acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting, congestive heart failure (New York Heart Association NYHA Grade > Grade 2), Poor control or arrhythmia requiring pacemaker therapy, Uncontrolled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg);
- Active infections, including: a)HIV (HIV 1/2 antibody) positive; b)Active hepatitis B (HBsAg positive and abnormal liver function); c)Active hepatitis C (HCV antibody positive or HCV RNA≥10^3 copy/ ml and abnormal liver function); d)Active tuberculosis; e)Other uncontrolled active infections (CTCAE V5.0> level 2);
- Other significant clinical and laboratory abnormalities, the researchers believe affect safety evaluation, such as: uncontrolled diabetes, chronic kidney disease, peripheral neuropathy (CTCAE V5.0) of grade II or above, thyroid dysfunction, etc.
- Has not recovered from surgery, such as the presence of unhealed incisions or severe postoperative complications;
- Received any live attenuated vaccine within 4 weeks of admission or during the study period;
- Pregnant or lactating women, as well as women or men with fertility who are unwilling or unable to take effective contraception;
- A history of alcohol, psychotropic or other substance abuse within 6 months;
- Enrolled in other clinical trials within 4 weeks before admission.
- Failure to follow the study protocol for treatment or scheduled follow-up;
- Any other factors evaluated by investigators that patients cannot be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
Treatment with Donafenib 100mg PO BID,and anti-PD-1 antibody 3mg/kg ivgtt Q2W.
Treatment will last 6 months, unless the tumor recurrence.
|
Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free rate in one year
Time Frame: Through the study period, for 3 years
|
The cumulative percentage of patients without recurrence in the first year after the primary surgery
|
Through the study period, for 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free survival
Time Frame: Through the study period, for 3 years
|
The period from the first study treatment to disease recurrence
|
Through the study period, for 3 years
|
Overall survival
Time Frame: Through the study period, for 3 years
|
The period from the first study treatment to any cause of death
|
Through the study period, for 3 years
|
ECOG physical condition 8/5000 ECOG physical condition
Time Frame: Through the study period, for 3 years
|
The changes of physical condition evaluated according to the criteria of Eastern Cooperative Oncology Group
|
Through the study period, for 3 years
|
FACT-Hep QLQ
Time Frame: Through the study period, for 3 years
|
The change of the quality of life
|
Through the study period, for 3 years
|
Alpha fetoprotein
Time Frame: Through the study period, for 3 years
|
The change of AFP
|
Through the study period, for 3 years
|
Adverse effects
Time Frame: Through the study period, for 3 years
|
Adverse events occurring through the study treatment, such as abnormalities or changes in laboratory examinations, physical examinations, vital signs, etc.
|
Through the study period, for 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CISLD-8
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Donafenib and anti-PD-1 antibody
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Shanghai Zhongshan HospitalRecruiting
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.Completed
-
Henlix, IncUnknown
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingExtensive Stage Small Cell Lung Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
Guangzhou Gloria Biosciences Co., Ltd.CompletedAdvanced Solid TumorsChina